---
document_datetime: 2025-12-02 05:19:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/savene.html
document_name: savene.html
version: success
processing_time: 0.1095969
conversion_datetime: 2025-12-28 03:51:01.089541
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Savene

[RSS](/en/individual-human-medicine.xml/66657)

##### Authorised

This medicine is authorised for use in the European Union

dexrazoxane Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Savene](#more-information-on-savene-748)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Savene. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Savene.

Expand section

Collapse section

## What is Savene?

Savene is a powder and diluent that are made up into a solution for infusion (drip into a vein). It contains the active substance dexrazoxane.

## What is Savene used for?

Savene is used to treat extravasation of anthracyclines (a group of anticancer medicines). Extravasation happens when an anticancer medicine that is normally injected into a vein leaks or is accidentally injected in the tissue surrounding the vein, where it can cause serious damage.

Because the number of patients who have extravasation of anthracyclines is low, the condition is considered 'rare', and Savene was designated an 'orphan medicine' (a medicine used in rare diseases) on 19 September 2001.

The medicine can only be obtained with a prescription.

## How is Savene used?

Savene must be used under the supervision of a doctor who has experience in the use of anticancer medicines.

The first infusion of Savene is given as soon as possible after the accident, and no later than six hours after it happened. Two further infusions are then given, one on day 2 and another on day 3, at the same time as the first infusion. The infusion should last between one and two hours, and be given at a site other than where the extravasation happened.

## How does Savene work?

The active substance in Savene, dexrazoxane, is an antidote to anthracyclines. The way it works is not entirely clear, but may be linked to the way the medicine attaches to iron in the body to form a 'chelate' and to its effect on some enzymes, such as topoisomerase II. Together, these effects can reduce the amount of tissue damage caused by anthracycline extravasation.

Dexrazoxane has been in use since the 1990s as a medicine to help prevent the cardiomyopathy (harm to the heart muscle) associated with the use of anthracyclines.

## How has Savene been studied?

Savene has been tested in two main studies involving a total of 80 patients who had extravasation of anthracyclines such as epirubicin or doxorubicin. Savene was not compared with any other medicines in these studies. The studies looked at how many patients needed surgery to correct the damage due to the extravasation.

## What benefit has Savene shown during the studies?

Only one patient among the 54 in whom the effectiveness of Savene could be measured had tissue damage requiring surgery.

## What is the risk associated with Savene?

The most common side effects with Savene (seen in more than 1 patient in 10) are nausea (feeling sick), and pain and infection at the site of the injection. Patients can also develop low blood levels of white blood cells and platelets. Although this may be caused by their anticancer treatment, it can also be caused by Savene, because it is a cytotoxic (a medicine that destroys cells that are multiplying) that can affect the bone marrow. Patients will be monitored for these side effects before, during and after treatment. For the full list of all side effects reported with Savene, see the package leaflet.

Savene should not be used in people who may be hypersensitive (allergic) to dexrazoxane or any of the other ingredients. It must not be used in women who could become pregnant or who are breastfeeding, or in patients receiving vaccination against yellow fever.

## Why has Savene been approved?

Anthracycline extravasation is a condition that can currently be managed using various methods, but for which there is no standard authorised treatment. The CHMP concluded that Savene had shown its ability to treat anthracycline extravasation, allowing patients to continue their anticancer treatment. The Committee decided that Savene's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Savene

The European Commission granted a marketing authorisation valid throughout the European Union for Savene on 28 July 2006.

For more information about treatment with Savene, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Savene : EPAR - Summary for the public

English (EN) (57.75 KB - PDF)

**First published:** 05/09/2006

**Last updated:** 16/08/2011

[View](/en/documents/overview/savene-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-419)

български (BG) (98.4 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/bg/documents/overview/savene-epar-summary-public_bg.pdf)

español (ES) (118.71 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/es/documents/overview/savene-epar-summary-public_es.pdf)

čeština (CS) (147.18 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/cs/documents/overview/savene-epar-summary-public_cs.pdf)

dansk (DA) (118.37 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/da/documents/overview/savene-epar-summary-public_da.pdf)

Deutsch (DE) (121.75 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/de/documents/overview/savene-epar-summary-public_de.pdf)

eesti keel (ET) (117.99 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/et/documents/overview/savene-epar-summary-public_et.pdf)

ελληνικά (EL) (169.69 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/el/documents/overview/savene-epar-summary-public_el.pdf)

français (FR) (119.04 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/fr/documents/overview/savene-epar-summary-public_fr.pdf)

italiano (IT) (121.17 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/it/documents/overview/savene-epar-summary-public_it.pdf)

latviešu valoda (LV) (146 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/lv/documents/overview/savene-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (144.88 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/lt/documents/overview/savene-epar-summary-public_lt.pdf)

magyar (HU) (142.94 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/hu/documents/overview/savene-epar-summary-public_hu.pdf)

Malti (MT) (85.71 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/mt/documents/overview/savene-epar-summary-public_mt.pdf)

Nederlands (NL) (120.32 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/nl/documents/overview/savene-epar-summary-public_nl.pdf)

polski (PL) (147.16 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/pl/documents/overview/savene-epar-summary-public_pl.pdf)

português (PT) (118.55 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/pt/documents/overview/savene-epar-summary-public_pt.pdf)

română (RO) (143.65 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/ro/documents/overview/savene-epar-summary-public_ro.pdf)

slovenčina (SK) (144.89 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/sk/documents/overview/savene-epar-summary-public_sk.pdf)

slovenščina (SL) (141.26 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/sl/documents/overview/savene-epar-summary-public_sl.pdf)

Suomi (FI) (120.51 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/fi/documents/overview/savene-epar-summary-public_fi.pdf)

svenska (SV) (120.04 KB - PDF)

**First published:**

05/09/2006

**Last updated:**

16/08/2011

[View](/sv/documents/overview/savene-epar-summary-public_sv.pdf)

## Product information

Savene : EPAR - Product Information

English (EN) (317.26 KB - PDF)

**First published:** 15/02/2008

**Last updated:** 06/09/2024

[View](/en/documents/product-information/savene-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-954)

български (BG) (516.34 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/bg/documents/product-information/savene-epar-product-information_bg.pdf)

español (ES) (436.89 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/es/documents/product-information/savene-epar-product-information_es.pdf)

čeština (CS) (518.53 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/cs/documents/product-information/savene-epar-product-information_cs.pdf)

dansk (DA) (457.86 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/da/documents/product-information/savene-epar-product-information_da.pdf)

Deutsch (DE) (475.52 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/de/documents/product-information/savene-epar-product-information_de.pdf)

eesti keel (ET) (409.16 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/et/documents/product-information/savene-epar-product-information_et.pdf)

ελληνικά (EL) (492.83 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/el/documents/product-information/savene-epar-product-information_el.pdf)

français (FR) (492.88 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/fr/documents/product-information/savene-epar-product-information_fr.pdf)

hrvatski (HR) (546.77 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/hr/documents/product-information/savene-epar-product-information_hr.pdf)

íslenska (IS) (439.43 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/is/documents/product-information/savene-epar-product-information_is.pdf)

italiano (IT) (493.23 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/it/documents/product-information/savene-epar-product-information_it.pdf)

latviešu valoda (LV) (538.27 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/lv/documents/product-information/savene-epar-product-information_lv.pdf)

lietuvių kalba (LT) (475.02 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/lt/documents/product-information/savene-epar-product-information_lt.pdf)

magyar (HU) (509.81 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/hu/documents/product-information/savene-epar-product-information_hu.pdf)

Malti (MT) (564.88 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/mt/documents/product-information/savene-epar-product-information_mt.pdf)

Nederlands (NL) (423.25 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/nl/documents/product-information/savene-epar-product-information_nl.pdf)

norsk (NO) (446.39 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/no/documents/product-information/savene-epar-product-information_no.pdf)

polski (PL) (521.01 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/pl/documents/product-information/savene-epar-product-information_pl.pdf)

português (PT) (435.64 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/pt/documents/product-information/savene-epar-product-information_pt.pdf)

română (RO) (494.22 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/ro/documents/product-information/savene-epar-product-information_ro.pdf)

slovenčina (SK) (555.93 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/sk/documents/product-information/savene-epar-product-information_sk.pdf)

slovenščina (SL) (467.75 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/sl/documents/product-information/savene-epar-product-information_sl.pdf)

Suomi (FI) (434.27 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/fi/documents/product-information/savene-epar-product-information_fi.pdf)

svenska (SV) (434.18 KB - PDF)

**First published:**

15/02/2008

**Last updated:**

06/09/2024

[View](/sv/documents/product-information/savene-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0052 22/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Savene : EPAR - All Authorised presentations

English (EN) (68.49 KB - PDF)

**First published:** 07/09/2006

**Last updated:** 30/01/2019

[View](/en/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-348)

български (BG) (55.07 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/bg/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_bg.pdf)

español (ES) (40.21 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/es/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.27 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/cs/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (41.99 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/da/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (41.92 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/de/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.88 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/et/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.08 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/el/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_el.pdf)

français (FR) (39.73 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/fr/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (95.16 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/hr/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.05 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/is/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_is.pdf)

italiano (IT) (39.56 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/it/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.88 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/lv/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.69 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/lt/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (48.59 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/hu/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (57.52 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/mt/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.65 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/nl/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (41.12 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/no/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.22 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/pl/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_pl.pdf)

português (PT) (41 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/pt/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.97 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/ro/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.91 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/sk/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (46.75 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/sl/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.28 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/fi/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (40.03 KB - PDF)

**First published:**

07/09/2006

**Last updated:**

30/01/2019

[View](/sv/documents/all-authorised-presentations/savene-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Savene Active substance dexrazoxane hydrochloride International non-proprietary name (INN) or common name dexrazoxane Therapeutic area (MeSH) Extravasation of Diagnostic and Therapeutic Materials Anatomical therapeutic chemical (ATC) code V03AF02

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Savene is indicated for the treatment of anthracycline extravasation.

## Authorisation details

EMA product number EMEA/H/C/000682 Marketing authorisation holder

CNX Therapeutics Ireland Limited

5th Floor Rear Connaught House 1 Burlington Road Dublin 4 Dublin Ireland

Marketing authorisation issued 27/07/2006 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Savene : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (217.51 KB - PDF)

**First published:** 15/02/2008

**Last updated:** 06/09/2024

[View](/en/documents/procedural-steps-after/savene-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Savene-H-C-682-PSUSA-01001 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/84011/2015

English (EN) (66.98 KB - PDF)

**First published:** 06/02/2015

**Last updated:** 06/02/2015

[View](/en/documents/scientific-conclusion/savene-h-c-682-psusa-01001-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Savene : EPAR - Scientific Discussion

English (EN) (291.78 KB - PDF)

**First published:** 07/09/2006

**Last updated:** 07/09/2006

[View](/en/documents/scientific-discussion/savene-epar-scientific-discussion_en.pdf)

Savene : EPAR - Procedural steps taken before authorisation

English (EN) (34.87 KB - PDF)

**First published:** 07/09/2006

**Last updated:** 07/09/2006

[View](/en/documents/procedural-steps/savene-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Savene

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu301059) on 19 September 2001. Savene was withdrawn from the Community register of orphan medicinal products in August 2016 at the end of the 10-year period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/09/2024

## Share this page

[Back to top](#main-content)